Skip to main content

Long-term survivors of glioblastoma: clinical features and molecular analysis

Acta Neurochirurgica volume 151, pages 1349–1358 (2009)Cite this article

Abstract

Background

Glioblastoma is a highly lethal neoplasm with a median survival of 12–14 months; only 2–5% of patients survive >3 years.

Methods

At our institute, patients with glioblastoma are initially treated with maximum tumor resection followed by radiation and the intravenous injection of nimustine hydrochloride (ACNU).

Results

Using this strategy, 18 of 123 (14.6%) patients treated at our hospital survived >3 years; 7 manifested no recurrence, and the other 11 had early recurrence and received additional therapies. To identify factors associated with prolonged survival, we compared these patients with 21 short-term (<1.5 years) glioblastoma survivors. In the long-term survivors, the MGMT promoter methylation was significantly more frequent. The rate of p53 mutation was lower, and the rate of PTEN mutations and the proliferation index were slightly higher in short-term survivors.

Conclusion

By multivariate analysis, we found that a younger age and MGMT promoter methylation were significant favorable factors in patients with glioblastoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

Abbreviations

STS:

short-term survivors

LTS:

long-term survivors

ACNU:

nimustine hydrochloride

MSP:

methylation specific PCR

QRT-PCR:

quantitative real-time reverse transcription PCR

TTP:

time to progression

OS:

overall survival

RS:

radiosurgery

RT:

radiation therapy

ICE:

isfosfamide + cisplatin + etoposide

MTX:

methotrexate

GAPDH:

glyceraldehydes-3-phosphate dehydrogenase

References

  1. Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, Lapierre F, Larsen CJ, Karayan-Tapon L (2004) Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68:275–283

    Article  CAS  PubMed  Google Scholar 

  2. Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174

    Article  CAS  PubMed  Google Scholar 

  3. Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59:1617–1625

    Article  CAS  PubMed  Google Scholar 

  4. Burton EC, Lamborn KR, Forsyth P, Scott J, O’Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O’Neill BP, Jenkins RB, Aldape KD (2002) Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8:180–187

    CAS  PubMed  Google Scholar 

  5. Chandler KL, Prados MD, Malec M, Wilson CB (1993) Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32:716–720

    Article  CAS  PubMed  Google Scholar 

  6. Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley BC, Braithwaite AW, Reddel RR, Royds JA (2006) Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 66:6473–6476

    Article  CAS  PubMed  Google Scholar 

  7. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869

    Article  PubMed  Google Scholar 

  8. Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767–775

    Article  CAS  PubMed  Google Scholar 

  9. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797

    CAS  PubMed  Google Scholar 

  10. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354

    Article  CAS  PubMed  Google Scholar 

  11. Fine HA (1994) The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20:111–120

    Article  CAS  PubMed  Google Scholar 

  12. Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci AC, Bret P (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7:899–904

    CAS  PubMed  Google Scholar 

  13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  CAS  PubMed  Google Scholar 

  14. Hsieh PC, Chandler JP, Bhangoo S, Panagiotopoulos K, Kalapurakal JA, Marymont MH, Cozzens JW, Levy RM, Salehi S (2005) Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery 57:684–692

    Article  PubMed  Google Scholar 

  15. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349–357

    Article  PubMed  Google Scholar 

  16. Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C (2000) Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6:3743–3937

    Google Scholar 

  17. Knobbe CB, Reifenberger G (2003) Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13:507–518

    CAS  PubMed  Article  Google Scholar 

  18. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma Network (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596–2606

    Article  PubMed  Google Scholar 

  19. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M (2007) Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 83:91–93

    Article  CAS  PubMed  Google Scholar 

  20. Morita M, Rosenblum MK, Bilsky MH, Fraser RA, Rosenfeld MR (1996) Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 27:259–266

    Article  CAS  PubMed  Google Scholar 

  21. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899

    Article  CAS  PubMed  Google Scholar 

  22. Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF (1996) Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J Biol Chem 271:13916–13924

    Article  CAS  PubMed  Google Scholar 

  23. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051–4058

    Article  CAS  PubMed  Google Scholar 

  24. Roth JG, Elvidge AR (1960) Glioblastoma multiforme: a clinical survey. J Neurosurg 17:736–750

    Article  CAS  PubMed  Google Scholar 

  25. Salford LG, Brun A, Nirfalk S (1988) Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69:506–509

    Article  CAS  PubMed  Google Scholar 

  26. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM (1998) Long-term survival in patients with supratentorial glioblastoma. J Neurooncol 36:61–64

    Article  CAS  PubMed  Google Scholar 

  27. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46:183–188

    Article  CAS  PubMed  Google Scholar 

  28. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, Tsuiki H, Tada K, Kuratsu J, Ishimaru Y, Ushio Y (2004) The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101:219–226

    Article  PubMed  Google Scholar 

  29. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J, Ushio Y (2002) Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95:249–257

    Article  CAS  PubMed  Google Scholar 

  30. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256

    Article  CAS  PubMed  Google Scholar 

  31. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, ALA-Glioma Study Group (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401

    Article  CAS  PubMed  Google Scholar 

  32. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  33. Tanaka S, Oka H, Fujii K, Watanabe K, Nagao K, Kakimoto A (2005) Quantitation of O6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas. Cell Mol Neurobiol 25:1067–1071

    Article  PubMed  Google Scholar 

  34. Vertosick FT Jr, Selker RG (1992) Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 38:359–363

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health and Welfare in Japan to T.T. We thank Nippon Gene Research Laboratories Inc. for QRT-PCR and direct sequencing analysis.

Author information

Affiliations

  1. Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan

    Yukihiko Sonoda, Toshihiro Kumabe, Tomoo Inoue, Masayuki Kanamori & Teiji Tominaga

  2. Division of Pathology, Tohoku University Hospital, Sendai, Miyagi, Japan

    Mika Watanabe

  3. Department of Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

    Yoichi Nakazato

Authors
  1. Yukihiko Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshihiro Kumabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mika Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoichi Nakazato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoo Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayuki Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teiji Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukihiko Sonoda.

Additional information

Comment

The most reliable marker in gliomas for biological behavior has been the 1p19q abnormality described in oligodendroglial tumors. Concerning the pure astrocytic tumors, no other marker has been described that has predictive value. Early indications from a few years ago indicated that those patients who received nitrosoureas were more likely to do better if the promoter region of the MGMT gene was methylated. This study seems to corroborate this finding and indeed moves the MGMT promoter methylation status into the forefront in terms of its being predictive for outcome in patients with high-grade gliomas. More retrospective studies are obviously required to decide whether or not this is a robust marker for long- versus short-term survival. This manuscript serves as an excellent substrate on which to base those studies.

Mitchel Berger

San Francisco, CA

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sonoda, Y., Kumabe, T., Watanabe, M. et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir 151, 1349–1358 (2009). https://doi.org/10.1007/s00701-009-0387-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-009-0387-1

Keywords

  • Glioblastoma
  • Long-term survival
  • MGMT
  • p53
  • PTEN